<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01378884</url>
  </required_header>
  <id_info>
    <org_study_id>AH 10-001</org_study_id>
    <nct_id>NCT01378884</nct_id>
  </id_info>
  <brief_title>The Use of Domperidone for Gastroparesis</brief_title>
  <official_title>Monitoring Study for the Use of Gastroparesis for Patient Who Have Failed Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allegiance Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allegiance Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether domperidone can be used safely and&#xD;
      effectively for patient with gastroparesis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals who have been diagnosed with gastroparesis and have failed at least one standard&#xD;
      therapy will be offered to trial domperidone as a possible remedy to their condition.&#xD;
      Patients on the medication will be expected to to be followed by the physician at 3 months, 6&#xD;
      months 12months, and then annually while on the medication. Any change or significant adverse&#xD;
      reaction to the medication or in their condition should be reported immediately to their&#xD;
      physician.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improved Gastric motility</measure>
    <time_frame>3 months</time_frame>
    <description>Patients will have improved gastric motility within three months of begining domperidone therpy</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Domeperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients to receive Domperidone for treatment of Gastroparesis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Domperidone</intervention_name>
    <description>Patient to receive treatment with Domperidone</description>
    <arm_group_label>Domeperidone</arm_group_label>
    <other_name>Domperidone / Motilium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female&#xD;
&#xD;
          2. Age 18 or older&#xD;
&#xD;
          3. Symptoms or manifestations secondary to GERD (e.g., persistent esophagitis, heartburn,&#xD;
             upper airway signs or symptoms or respiratory symptoms), gastrointestinal motility&#xD;
             disorders such as nausea, vomiting, severe dyspepsia or severe chronic constipation&#xD;
             that are refractory to standard therapy.&#xD;
&#xD;
          4. Subjects must have a comprehensive evaluation to eliminate other causes of their&#xD;
             symptoms.&#xD;
&#xD;
          5. Subject has signed informed consent for the administration of domperidone. The&#xD;
             informed consent informs the subject of potential adverse events including:&#xD;
&#xD;
               -  increased prolactin levels,&#xD;
&#xD;
               -  extrapyramidal side effects,&#xD;
&#xD;
               -  breast changes,&#xD;
&#xD;
               -  cardiac arrhythmias including QT prolongation, and&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of or current cardiac disease, including ischemic or valvular heart disease,&#xD;
             other structural heart defects, cardiomyopathy or congestive heart failure.&#xD;
&#xD;
          2. History of or current arrhythmias including ventricular tachycardia, ventricular&#xD;
             fibrillation and Torsade des Pointes. Subjects with minor forms of ectopy (PACs) are&#xD;
             not necessarily excluded.&#xD;
&#xD;
          3. Clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged&#xD;
             QT syndrome (QTc greater than 450 milliseconds for males, greater 470 milliseconds for&#xD;
             females) or family history prolonged QT syndrome.&#xD;
&#xD;
          4. Presence of a prolactinoma (prolactin-releasing pituitary tumor).&#xD;
&#xD;
          5. Conditions that result in electrolyte disorders, such as severe dehydration, vomiting,&#xD;
             malnutrition, eating disorders, renal diseases, or the use of potassium-wasting&#xD;
             diuretics or insulin in acute settings. (Note that the presence of vomiting, that may&#xD;
             accompany gastroparesis or pseudo-obstruction does not by itself exclude the subject -&#xD;
             only if accompanied by electrolyte disturbance must the subject be excluded.)&#xD;
&#xD;
          6. Pregnant or breast feeding female.&#xD;
&#xD;
          7. Known allergy to domperidone or any components of the domperidone formulation.&#xD;
&#xD;
          8. Significantly significant electrolyte disorders.&#xD;
&#xD;
          9. Gastrointestinal hemorrhage or obstruction.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan Cubas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allegiance Health Gastroenterology</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>February 3, 2010</study_first_submitted>
  <study_first_submitted_qc>June 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2011</study_first_posted>
  <last_update_submitted>March 18, 2013</last_update_submitted>
  <last_update_submitted_qc>March 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2013</last_update_posted>
  <responsible_party>
    <name_title>Ivan Cubas, MD</name_title>
    <organization>Allegiance Health Gastroenterology</organization>
  </responsible_party>
  <keyword>Gastroparesis</keyword>
  <keyword>Domperidone</keyword>
  <keyword>Motilium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Domperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

